Insider Selling: Guardant Health (NASDAQ:GH) Director Sells $2,253,485.60 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Ian Clark sold 14,180 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $158.92, for a total value of $2,253,485.60. Following the sale, the director owned 2,975 shares in the company, valued at $472,787. The trade was a 82.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Guardant Health Price Performance

NASDAQ:GH opened at $168.48 on Friday. Guardant Health, Inc. has a 12-month low of $51.44 and a 12-month high of $176.58. The firm has a market capitalization of $22.61 billion, a P/E ratio of -48.27 and a beta of 1.60. The business has a 50 day simple moving average of $147.02 and a 200 day simple moving average of $115.20.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GH shares. TD Cowen upped their price target on shares of Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Barclays upped their target price on shares of Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Finally, Stephens raised their price target on shares of Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $183.78.

Hedge Funds Weigh In On Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Alpine Woods Capital Investors LLC acquired a new position in Guardant Health during the 2nd quarter valued at about $237,000. Deutsche Bank AG bought a new stake in shares of Guardant Health during the 2nd quarter worth about $24,385,000. Perigon Wealth Management LLC acquired a new stake in shares of Guardant Health in the 2nd quarter worth approximately $1,073,000. Persistent Asset Partners Ltd acquired a new stake in shares of Guardant Health in the 2nd quarter worth approximately $641,000. Finally, OneDigital Investment Advisors LLC bought a new position in shares of Guardant Health in the second quarter valued at approximately $345,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.